Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 11/20 | 0.41 |
| ▸ | PPARG | P37231 | 9/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.35 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3758035 | 0.91 | PPARA (0.42) | PPARAPPARG | |
| SCHEMBL3758032 | 0.91 | PPARA (0.42) | PPARAPPARG | |
| SCHEMBL3769106 | 0.88 | NPC1 (0.40) | PPARAPPARGKDM4EALDH1A1SLC6A4 | |
| SCHEMBL3763253 | 0.87 | PPARG (0.45) | PPARAPPARGALDH1A1MAPTTAS1R3 | |
| SCHEMBL3764573 | 0.86 | PPARA (0.47) | PPARAPPARGALDH1A1MAPTSLC6A4 | |
| SCHEMBL3960292 | 0.85 | PPARA (0.41) | PPARAPPARGKDM4EALDH1A1MAPT | |
| SCHEMBL3762987 | 0.85 | PPARA (0.50) | PPARAPPARGMAPT | |
| SCHEMBL3768052 | 0.84 | PPARA (0.49) | PPARAPPARGMAPT | |
| SCHEMBL3768798 | 0.84 | PPARG (0.52) | PPARAPPARGKDM4EALDH1A1MAPT | |
| SCHEMBL3758101 | 0.83 | PPARA (0.39) | PPARAPPARGALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268867-B2 | 1,3-dioxane carboxylic acids | CADILA HEALTHCARE LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-20100311795-A1 | 1,3-DIOXANE CARBOXYLIC ACIDS | CADILA HEALTHCARE LIMITED (IN) | 2010-12-09 | — | — | US | claimed |
| EP-1989192-B1 | 1,3-DIOXANE CARBOXYLIC ACIDS | CADILA HEALTHCARE LTD (IN) | 2009-07-22 | — | — | EP | claimed |
| EP-1989192-A2 | 1,3-DIOXANE CARBOXYLIC ACIDS | CADILA HEALTHCARE LTD. (IN) | 2008-11-12 | — | — | EP | claimed |
| WO-2007099553-A2 | 1,3-DIOXANE CARBOXYLIC ACIDS | CADILA HEALTHCARE LIMITED (IN) | 2007-09-07 | — | — | WO | claimed |
| US-8268867-B2 | 1,3-dioxane carboxylic acids | CADILA HEALTHCARE LIMITED (IN) | 2012-09-18 | — | — | US | disclosed |
| US-20100311795-A1 | 1,3-DIOXANE CARBOXYLIC ACIDS | CADILA HEALTHCARE LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| EP-1989192-B1 | 1,3-DIOXANE CARBOXYLIC ACIDS | CADILA HEALTHCARE LTD (IN) | 2009-07-22 | — | — | EP | disclosed |
| EP-1989192-A2 | 1,3-DIOXANE CARBOXYLIC ACIDS | CADILA HEALTHCARE LTD. (IN) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007099553-A2 | 1,3-DIOXANE CARBOXYLIC ACIDS | CADILA HEALTHCARE LIMITED (IN) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311795-A1 | 1,3-DIOXANE CARBOXYLIC ACIDS | SLC10A1, CYP11B2, UGT1A1 | PPARA 1132/4885PPARG 636/4885KDM4E 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.